(CercleFinance.com) – Nicox gains more than 4% after the publication of new data on NCX 470 showing improvements in ocular hemodynamics and retinal cell physiology, in the Journal of Ocular Pharmacology and Therapeutics.
“NCX 470 may have best-in-class efficacy in reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension,” said Doug Hubatsch, chief scientific officer of Nicox.
NCX 470 is currently being evaluated in two international Phase 3 clinical studies, Mont Blanc and Denali, aimed at demonstrating non-inferiority and, if achieved, statistical superiority in reducing intraocular pressure compared to Xalatan.